| Vol. 6.11 – 25 March, 2022 |
| |
|
|
| Scientists reported a targeted antifibrotic peptide-delivery system in which fibroblast activation protein, which was overexpressed in fibrotic regions of the liver, liberated the antifibrotic peptide melittin by cleaving a fibroblast activation protein-specific site in the peptide. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators observed that chromodomain Y-like 2 (CDYL2) was down-regulated in human primary HCC tissues and the low levels of CDYL2 expression were correlated with poor survival. [Oncogene] |
|
|
|
| The proteomic characterization of the peritumor microenvironment of HCC revealed that the entire processes of HCC occurrence and progression differed substantially. [Oncogene] |
|
|
|
| The authors developed a tumor “cruise missile” designed to enhance the accuracy of small HCC visualization to 85.7% using combined ultrasound/photoacoustic imaging in complex liver environment, which facilitated sequential catalytic targeted therapy for small HCC. [Journal of Nanobiotechnology] |
|
|
|
| Researchers found that the expression of CMTM6 was significantly reduced in HCC and predicted better prognosis of HCC patients. Through in vitro and in vivo experiments, CMTM6 was shown to inhibit the proliferation of HCC cells by blocking the G1/S phase transition. [Cell Death & Disease] |
|
|
|
| Investigators assessed transcriptional diversity in 15 liver cancer patients by single-cell transcriptome analysis and observed that transcriptional diversity of tumor cells was associated with stemness in liver cancer patients. [Cell Death & Disease] |
|
|
|
| Scientists demonstrated that lysine acetyltransferase 6 A (KAT6A) expression was upregulated in HCC tissues and cell lines. Clinical analysis showed that increased KAT6A was significantly associated with malignant prognostic features and shorter survival. [British Journal of Cancer] |
|
|
|
| The authors used selective small molecule inhibitors of monoacylglycerol acyltransferase 2 (MGAT2) and MGAT3 to determine the contributions of these enzymes to triacylglycerol production in liver cells. [Scientific Reports] |
|
|
|
| RAB3B was identified as an up-regulated gene in both cancer stem-like sphere cells and prognostically poor hepatocellular carcinoma by RNA-sequencing. [BMC Cancer] |
|
|
|
| The bioactivities of inhibitors on PTEN adequate Huh7 and deficient Mahlavu cells were investigated with real time cell growth, cell cycle and cell migration assays. [BMC Cancer] |
|
|
|
|
| Investigators appraise the existing literature and current clinical trial landscape of neoadjuvant therapies in HCC. [Clinical Cancer Research] |
|
|
|
| Scientists summarize the current literature on the impact of hepatitis D virus (HDV) in HCC development and discuss the potential interplay between hepatitis B, HDV and neighboring liver tissue in liver carcinogenesis. [Liver International] |
|
|
|
| The authors provide an update on the regulation of noncoding RNAs in the crosstalk between macrophages and tumor cells in HCC. [Molecular Therapy-Oncolytics] |
|
|
|
|
| Oramed Pharmaceuticals, Inc. announced it has completed enrollment of all patients in a Phase II trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH). [Oramed Pharmaceuticals, Inc.] |
|
|
|
|
| May 4 – 7 San Francisco, California, United States |
|
|
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| Gilead Sciences – Foster City, California, United States |
|
|
|
| Amsterdam UMC – Amsterdam, Netherlands |
|
|
|
| NIH National Heart, Lung, and Blood Institute – Bethesda, Maryland, United States |
|
|
|
|